31st March 2019

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department,
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A, Boulevard Joseph II
L-1840 Luxembourg

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company wishes to inform you that the US FDA conducted a product specific pre-approval (PAI) and Good Manufacturing Practices (GMP) inspection at its Kurkumbh plant from 11th March 2019 to 20th March 2019. The inspection covered 3 units at the plant. Post the conclusion of the inspection, the Company received 8 GMP observations. The Company also received 10 observations pertaining to the PAI for a novel technology product slated for approval beyond 2024. These observations are both product specific and GMP observations related to the manufacturing and quality processes. There are no data integrity (DI) observations. The Company is committed to addressing these observations and will submit its response to the agency within the stipulated time.

Kindly take the above information on record.

Thank you.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary